Peptide antibiotics are typically biosynthesized by one of two distinct machineries in a ribosome-dependent or -independent manner. Pheganomycin (PGM) (1) and related analogues consist of the nonproteinogenic amino acid (S)-2-(3,5-dihydroxy-4-hydroxymethyl)phenyl-2-guanidinoacetic acid (2) and a proteinogenic core peptide, making their origin uncertain. We report the identification of the biosynthetic gene cluster from Streptomyces cirratus responsible for PGM production. Surprisingly, the cluster contains a gene encoding multiple precursor peptides along with several genes plausibly encoding enzymes for the synthesis of amino acid 2. We identified pgm1, which has an ATP-grasp domain, as potentially capable of linking the precursor peptides with 2, and validate this hypothesis using deletion mutants and in vitro reconstitution. We document PGM1's substrate permissivity, which could be rationalized by a large binding pocket as confirmed via structural and mutagenesis experiments. This is the first example of cooperative peptide synthesis achieved by ribosomes and peptide ligases using a peptide nucleophile.
Introduction
Peptide antibiotics form a large subclass of natural products, including clinically important pharmaceuticals such as vancomycin and daptomycin 1 . Recent progress in genome sequencing techniques has uncovered the presence of novel genes responsible for the biosynthesis of this category of compounds. We often categorize naturally occurring peptides by their biosynthetic machineries: either ribosomally synthesized and post-translationally modified peptides (RiPPs) 2 or nonribosomal peptides (NRPs). Ribosomal peptide and NRP synthetases (NRPSs) using thiotemplate assembly logic produce RiPPs and NRPs, respectively 3 . In addition to these two machineries for peptide/amide-bond formation, amino acid ligases with ATP-grasp domains (ATP-grasp-ligases), tRNA-dependent aminoacyl transferase/cyclodipeptide synthases, stand-alone adenylation (A) domains and acyl-CoA synthetases (acyl-AMP-ligases) have been shown to catalyze amide-bond formations [4] [5] [6] .
Streptomyces cirratus produces structurally unique pheganomycins (PGMs), which show anti-mycobacteria activity 7 . PGM (1) contains two nonproteinogenic amino acids [(S)-2-(3,5-dihydroxy-4-hydroxymethyl)phenyl-2-guanidinoacetic acid (2) and (S)-2-amino-3,3-dimethylbutanoic acid (L-tert-Leu)] and two proteinogenic L-amino acids (Asn and Lys) in the order of (N-terminus)-2-Asn-L-tert-Leu-Lys-(C-terminus) (Fig. 1a) . PGM-D, PGM-DR and PGM-DGPT have the additional amino acids Asp, Asp-Arg and Asp-Gly-Pro-Thr, respectively, at the C-terminus of 1. Though the L-tert-Leu residue is nominally non-proteinogenic, it could be formed via methylation of the Val residue by a radical S-adenosyl methionine (SAM) enzyme, as shown in bottromycin biosynthesis 8, 9 , suggesting that 2 is the only true nonproteinogenic component. Vancomycin, which is known to be biosynthesized by NRPS machineries 10 , contains (S)-2-amino-2-(3,5-dihydroxyphenyl)acetic acid (3); because PGMs also contain the structurally-related 2, PGMs could logically be synthesized by NRPS. However, the peptide chain length differences and the type of C-terminal amino acid sequences in PGMs defy this expectation, because the substrate specificities of the A-domain of NRPSs are strict and there are few examples of this type of diversity in peptides synthesized by NRPS. However, the ribosomally synthesized 3 cyanobactins provide one example of C-terminal amino acid diversity 11 . In sum, the origins of the PGMs is unclear.
To provide insights into this question, we report the biosynthetic machinery responsible for the unique structural features of PGMs. We identified the biosynthetic gene cluster responsible for 1 synthesis, which contained a gene encoding a precursor peptide including two core peptides, several genes plausibly encoding enzymes for 2 biosynthesis and tailoring reactions. We also identify pgm1,
containing an ATP-grasp domain, as necessary for PGM productivity in cells, while recombinant PGM1 catalyzed the ATP-dependent peptide bond formation between 2 and representative peptide substrates. PGM1 accepted a variety of peptides as the nucleophile and we rationalize this flexibility via the crystal structure and mutational analyses of PGM1. This is the first example of cooperative peptide synthesis achieved by ribosomes and peptide ligases using a peptide as a nucleophile.
Results

Identification of the biosynthetic gene cluster for 1
PGMs have the 2 moiety, probably derived from 3, at the N-terminus. In vancomycin and teicoplanin biosynthesis, four enzymes, DpgA-DpgD catalyze the formation of 2-(3,5-dihydroxyphenyl)-2-oxoacetic acid, the deamination product of 3 12 . We therefore searched for orthologs of Dpg(s) in a draft genome database. Using BLAST search, we identified three ORFs (PGM11, 10 and 9), which have high similarities to DpgA, B and C, respectively. In the flanking regions of the genes, we identified 18 additional genes (a total of 21 genes) that should form a cluster ( Fig. 1b and although three genes encoding stand-alone NRPSs, PGM21 with an A-domain, PGM20 with a Tdomain, and PGM19 with a C-domain, were present. An ORF with an ATP-grasp domain (PGM1) (Supplementary Fig. 1 ) also existed in the cluster. In the upstream and downstream regions of pgm1, there are two genes encoding an aldose 1-epimerase and a dehalogenase/phosphatase, though the utility of these genes in the construction of PGM is not obvious. We therefore examined the possibility that ribosome supplied the proteinogenic amino acids in PGMs because a putative peptidase gene (pgm14, 1159 amino acids), which is usually present in the biosynthetic gene clusters of ribosomally synthesized peptide antibiotics, exists in the cluster. We carefully searched for a small ORF that could encode a core peptide with an NVKDGPT and/or NVKDR sequence and identified an ORF (PGM2) composed of 38 amino acids (MEREIVWTEIEESDLAAVVSASNVKDGPTVSSSNVKDR) in the cluster (Fig. 1b) . This potential precursor peptide would clearly explain the C-terminal diversity of PGMs including differences in the length and kinds of amino acids (underlined in the above sequences). Based on these results, we hypothesized that NRPS (PGM19 to 21) or PGM1 catalyzes the peptide bond formation between 2 and the peptides, although there are no reports demonstrating that these machineries synthesize a peptide backbone.
Gene disruptions
To test the involvement of these genes in PGM biosynthesis, we first deleted the pgm2 gene encoding the precursor peptide by a gene replacement technique 13 . We successfully obtained pgm2-deletion mutants ( Supplementary Fig. 2 ). After cultivation of the mutants in liquid medium, we monitored the production of PGMs by LC-ESI-MS analysis and confirmed that the mutants produced no PGMs ( Supplementary Fig. 2c ), supporting our proposal that ribosome-dependent machinery supplied the proteinogenic precursor peptides.
We then examined whether the NRPSs participates in the biosynthesis of 1. We disrupted the pgm19 gene by the same method used for pgm2 disruption and examined the production of 1. As shown in Supplementary Fig. 3c , the mutant maintained the ability to produce 1, indicating that 5 PGM19 has no connection with 1 biosynthesis.
Finally, we disrupted pgm1 by the method described above. The mutant did not produce 1 ( Supplementary Fig. 4c ), showing that PGM1 is essential for 1 biosynthesis.
PGM1 catalyzed the peptide bond formation
The ATP-grasp domain is commonly found in enzymes from the ATP-dependent (ADP-forming)
carboxylate-amine/thiol ligase superfamily 14, 15, 16, 17, 18 . We prepared a recombinant C-terminal His-tagged PGM1 protein ( Supplementary Fig. 5 ). Gel filtration analysis indicated a molecular mass of 99.8 kDa, suggesting that PGM1 forms a homodimer structure ( Supplementary Fig. 5b ). The homodimer structure was also supported by a crystal structure (see below). We used PGM1 to catalyze the reaction of the substrates, (S)-2-guanidino-2-phenylacetic acid (4) (Fig. 2a) and NVKDR. In the presence of ATP and Mg 2+ , a product was specifically detected by HPLC analysis (Fig. 2b) , and its molecular mass was in good agreement with the estimated product by LC-ESI-MS analysis ( Supplementary Fig. 6 ). We purified the product (5) and determined its structure to be NVKDR with 4 at the N-terminus (Fig. 2c, and Supplementary Figs. [7] [8] [9] [10] [11] [12] [13] [14] by NMR analysis. This result confirmed that PGM1 catalyzed peptide bond formation between a nonproteinogenic amino acid and a core peptide.
To examine the activation mechanism of the substrate, we attempted to detect phosphorylated 4
by LC-ESI-MS analysis, but all trials failed despite employing several different reaction and analytical conditions (data not shown). As an alternative approach, we tried detecting the byproduct, ADP, in the reaction mixture containing substrate (4) as the sole substrate. As shown in the Supplementary Fig. 15a , we could detect ADP. However, less ADP also formed in the control experiment without 4 probably because of a contamination of a phosphatase in recombinant PGM1.
The calculated concentration of ADP specifically formed by PGM1 was 0.048 mM, which 6 corresponds to almost half concentration of recombinant PGM1 (0.083 mM) used in the experiment.
We also quantitatively measured the amounts of consumed substrate (ATP) and formed products (5, ADP and Pi) and confirmed these to be stoichiometrically equivalent ( Supplementary Fig. 15b ).
Furthermore, we confirmed no formation of AMP ( Supplementary Fig. 15c ). Taken together, these data suggest, but do not definitively show, that PGM1 activates its substrate by phosphorylation.
Enzymatic properties of PGM1
We examined the substrate specificity of PGM1 with the compounds shown in Fig. 2a as N Table 3 ).
Structure of PGM1
To understand the structural basis for the remarkable substrate tolerance we observed, we solved the crystal structures of PGM1-AMP complex ( Aquifex aeolicus (PDB entry 2YW2) 21 , N 5 -carboxyaminoimidazole ribonucleotide synthetase (N 5 -CAIR) of Aspergillus clavatus (PDB entry 3K5H) 22 , glycinamide ribonucleotide transformilase (PurT) of Escherichia coli (PDB entry 1KJ8) 23 , and L-amino acid ligase (LAL) of Bacillus licheniformis (PDB entry 3VOT) 24 , respectively. In the PurD forms, the closed form represents the initial phosphorylation and second amido-bond formation stages of the enzyme reaction.
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Comparisons of the PGM1 structures with the opened form of PurD of E. coli (PDB entry 1GSO) 25 and the closed form of PurD of A. aeolicus (PDB entry 2YW2) 21 revealed that the structure of PGM1 obtained here was in a closed conformation ( Supplementary Fig. 35 ).
The central core and upper structures also formed a large cavity at the center of the PGM1 structure and a long cleft connecting from the large cavity lying at the boundary of the N and B domains (Fig. 4b) . The ATP-binding site was located deep inside the large cavity, and Arg335, corresponding to the putative catalytic Arg in PurDs 21 , sat at the intersection of the ATP-binding and the N-terminus substrate-binding sites by protruding its side-chain toward the ATP-binding site.
PGM1 possessed most of the conserved residues lining the ATP-binding site, including Arg335, in a location and orientation similar to those of PurD enzymes ( Supplementary Fig. 36 ). However, the large cavity and the cleft created an unusual active site in PGM1 (Supplementary Figs. 37 and 38).
Model building and structure-based mutagenesis of PGM1
To further clarify the intimate structural details of substrate and product specificities of PGM1, we carried out model building studies and investigated the effect of the mutagenesis of key amino acids on enzyme activity using 4 as the N-terminus substrate, and the NVKDR and NVKDGPT peptides as the cosubstrates (Supplementary Table 4) . A PGM1-ATP-2 ternary complex model structure predicted that the carboxyl group of 2 would be located near the γ-phosphate of ATP and the side chain amidino group of the putative catalytic residue Arg335 (Fig. 4c) . Moreover, the amidino group of 2 occupied near the side chains of Glu255, Asp318, Ser316, Thr337 and Ser339. Indeed, the R335Q, R335N and R335M substitutions completed loss of enzyme ability. In addition to these mutants, the E255D, E255S, S316D and S339A substitutions at the N-terminus substrate-binding site resulted in loss of enzyme activity. Thus, we suspect PGM1 initiates the reaction by a nucleophilic attack of the carboxylic anion of the N-terminus substrate on the γ-phosphate of ATP.
Conversely, a structure model of PGM1-ADP-phosphorylated 2-NVKDR peptide quaternary complex predicted that the N-terminal Asn of the peptide places near the phosphate moiety of the phosphorylated 2 (Fig. 4d) . To bind here, Ser190 and Gly191-located at the entrance to the cleft-would be well placed to recognize the side chain of the N-terminal Asn of the peptide. In contrast, the C-terminal Arg of the peptide would be located near Ala14, Glu15 and Thr17 on the cleft. A similar case was found in the quaternary model structure of the PGM1-ADP-phosphorylated 2-NVKDGPT peptide complex, in which the C-terminal Thr located near Ser190 and Gln186 (Fig.   4e ). In line with these models, S190L and S190A substitutions showed a 77% and 43% decrease in the 5-forming activity, respectively, depending on the bulkiness of the mutated residues. Furthermore, when we used NVKDGPT as the counter substrate instead of NVKDR, the S190L and S190A
substitutions were more effective (81% and 45% decrease). More importantly, the mutagenesis studies also revealed that the small-to-large A14R and A14Q substitutions near the end of the cleft showed a 49% and 47% decrease in the 5-forming activity and a 45% and 46% decrease in the 4-primed NVKDGPT forming activity, respectively. In contrast, the A14L substitution, using a less bulky residue than Arg and Gln, had almost no effect on the enzyme's activity. Thus, the steric contraction at this position significantly interrupted enzyme activity.
Discussion
In this study, we revealed that two distinct machineries-a new type of peptide ligase and ribosomes-cooperated to synthesize 1. PGM1 uses an ATP-grasp domain to catalyze peptide bond formation via activation of the nonproteinogenic phenylglycine derivatives, likely by phosphorylation and successive nucleophilic attack by the ribosomally produced peptides. Although we can find many enzymes with an ATP-grasp domain in genomic databases by searching conserved domains such as Pfam 26 , most of their functions remain unknown. Among the enzymes identified, approximately 20 catalyze an ATP-dependent phosphorylation of a carboxyl group of one substrate and a nucleophilic attack by an amino or imino group nitrogen of another substrate. In these reactions, the first substrate is a protein, a short peptide, an amino acid, or an organic/inorganic acid, but an amino acid, a thiol group (CoA), a biotinylated protein, a ribonucleotide derivative, an inositol derivative, or an ammonium ion is the second substrate 14 . Therefore, PGM1 is the first example in which a peptide is used as the nucleophile and, moreover, of ribosomes and peptide 10 ligases cooperatively synthesizing a single peptide backbone (Fig. 5) . To date, there are other examples of machinery that combine two proteins/peptides such as ubiquitin ligase found in the ubiquitin-proteasome complex 27 , sortase 28 , which participates in peptidoglycan biosynthesis, and intein, which is active in protein splicing 29 . However, PGM1 uses a completely distinct mechanism from these enzymes, and thus defines a new type of machinery.
The crystal structure of PGM1 demonstrated that PGM1 has an unusually large active site consisting of a large cavity and a long cleft. This type of large active site has never been reported in the ATP-grasp superfamily enzymes. The site-directed mutagenesis studies coupled with docking simulations suggested that both the amidino and terminal carboxyl groups of the guanidinoacetic acid scaffold of the substrate molecules might be responsible for the binding to PGM1. The findings would explain the N-terminus substrate specificities of PGM1, which no longer accepted 3, 3-guanidinopropanoic acid, 4-guanidinobutanoic acids, and L-amino acids, because of the loss of both interactions between the amidino or terminal carboxyl group of the substrate and PGM1.
The most interesting functional feature of PGM1 is the remarkable second substrate tolerance.
The PGM1 structure and mutagenesis studies suggested that the large cavity at the center of the PGM1 structure and the long cleft connecting the large cavity lying at the boundary of the N and B domains enabled to accept many peptides composed of different lengths and kinds of amino acids as the nucleophiles.
The broad substrate specificity of PGM1 enabled us to synthesize various derivatives of 1, which may have higher activity against mycobacteria as well as other biological activities. Moreover, as exemplified by apidaecin, the attachment of nonproteinogenic amino acids at the N-terminus of various antibiotic peptides by PGM1 may improve the proteolytic stability of short peptides, which are usually unstable in physiological environments because of their susceptibility to degradation. orthologs of pgm7 to pgm12 (SGM_5887 to SGM_5892 and SSFG_06973 to SSFG_06978) in the regions near the pgm1 orthologs. These facts strongly suggest that both strains produce a peptide compound with derivatives of 2 at the N-terminus. In contrast, other strains may produce peptides with an amino acid or its derivative at the N-terminus, because no orthologs of pgm7 to pgm12 exist in the flanking regions of the pgm1 ortholog. Using these PGM1 orthologs, we may develop a simple synthetic method to produce more diverse peptides.
Methods
General. Sequence analysis of PCR fragments was performed by the dideoxy chain termination method with an automatic DNA sequencer (Li-Cor, model 4000L, Lincoln, NE, USA). Cell disruption was performed with an ultrasonic disruptor (TOMY, UD-200, Tokyo, Japan). Analysis of the samples during protein purification was performed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were visualized by Coomassie brilliant blue staining.
Protein concentration was determined by the kit (Sigma-Aldrich, B6916) with bovine serum albumin as a standard. Compound 4 was chemically synthesized from phenylglycines and formamidinesulfinic acid 34 . All the synthetic peptides were obtained from Life Technologies Japan (Tokyo, Japan). The dipeptides and the tetrapeptide (MRFA) were purchased from AnaSpec (Fremont, CA, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. Apidaecin and its derivative were kindly provided by Prof. S. Taguchi (Hokkaido University, Sapporo, Japan). Other chemicals were purchased from Sigma-Aldrich and Wako Pure Chemical Industry (Osaka, Japan).
Purity of these compounds was examined by HPLC.
Strain and plasmids.
Streptomyces cirratus strain MD227-A9 was used for the production of PGM and the preparation of genomic DNA. Gene disruption. The pgm1, pgm2 and pgm19 genes were disrupted by double-crossover homologous recombination. To construct the gene disruption plasmids, two 2-kb DNA fragments carrying the upstream (EcoRI-XbaI fragment) and downstream (XbaI-HindIII fragment) regions of the target genes were amplified by PCR with the primer set listed in Supplementary Table 5 . After sequence confirmation, the fragments were inserted into the EcoRI/XbaI and XbaI/HindIII sites of pUC18 in the same direction as in the genomic region. The inserted DNAs were then digested with
EcoRI and HindIII, and inserted into the same sites of pWHM3 37 . The constructed plasmids were used to transform the 1 producer and the thiostrepton-resistant colonies were selected by the same method used for S. coelicolor A3(2) 38 . After protoplasting and regeneration of the transformants, thiostrepton-sensitive colonies were collected. Among them, a deletion mutant was selected by PCR analysis and the production of 1 was analyzed by LC-ESI-MS.
Cloning, overexpression and purification of PGM1. pgm1 was amplified by PCR using gene-specific primers (Supplementary Table 5 ). After subcloning and sequence confirmation, the DNA fragments obtained by digestion with NdeI and XhoI were ligated into the same sites of pET21b. E. coli BL21 (DE3) harboring the recombinant expression vector was grown in L-broth supplemented with 100 µg/mL ampicillin. The strain was grown at 37°C until the OD600 reached 0.5 and then isopropyl β-D-thiogalactopyranoside (0.5 mM) was added to the culture, followed by additional cultivation at 25°C for 18 h. Recombinant PGM1 was purified according to the manufacturer's protocol. After the purity of the recombinant PGM1 was checked by SDS-PAGE ( Supplementary Fig. 5a ), the enzyme was used for the in vitro assay. To determine the optimum temperature, the assay was conducted from 10 to 60°C. The assay mixture contained in a final volume of 100 μL was 50 mM Tris-HCl, pH 8.0, 50 µM NVKDR, 50 µM 4, 5 mM ATP, 5 mM Mg 2+ , and 4 µg of PGM1. The mixture was incubated at 30°C for 5 min.
For optimum pH analysis, the assay was conducted from pH 6.5 to 10 using 50 mM MES (pH 6.5 and 7), 50 mM Tris-HCl (pH 7.5 to 9), and 50 mM glycine-NaOH (pH 9 to 10). The assay mixture in each of the buffer contained in a final volume of 100 μL was 50 µM NVKDR, 50 µM 4, 5 mM ATP, 14 5 mM Mg 2+ , and 4 µg of PGM1. The mixture was incubated at 30°C for 5 min. Average value obtained by two independent experiments was shown.
To measure the amounts of consumed substrate (ATP) and formed products ( min; flow rate, 0.2 ml/min; cone voltage, 30 V in total and selected ion chromatograms.
When the peptides with internal Lys and Arg, the side chains of which can also be utilized as nucleophile, were used as substrates, the enzyme reaction mixtures were analyzed by LC-ESI-MS/MS (Esquire 4000, Bruker Japan, Yokohama, Japan) using a reversed-phase column When apidaecin and its derivative were used as the substrates, the assay mixture contained in a final volume of 100 μL, 50 mM Tris-HCl (pH 8.0), 1 mM 4, 2.5 µM apidaecin or its derivative, 10 mM ATP, 10 mM Mg 2+ and 4 µg of PGM1. After the reaction was incubated at 30°C overnight, the following products were analyzed by MALDI-TOF-MS analysis (Ultraflex III, Bruker Japan) with Single-wavelength anomalous diffraction (SAD) data of PGM1 apo and PGM1-AMP complex crystals were collected on beamline BL17A and BL5A at Photon Factory, respectively, under cryogenic conditions at −173°C. Wavelengths of 0.97939 Å at BL17A, and 0.97901 Å at BL5A were used for data collection based on the fluorescence spectrum of the Se K absorption edge 39 . The diffraction data were processed and scaled using XDS 40 . Se sites were determined and refined, and the initial phase of PGM1 apo was calculated with AutoSol in PHENIX 41, 42 . . A total of 98.2% of the residues in the PGM1 apo structure were in the most favored regions of the Ramachandran plot, and 1.7% were in the allowed regions, while a total of 97.2% of the residues in the PGM1-AMP complex structure were within the most favored regions of the Ramachandran plot, and 2.5% were in the allowed regions.
Preparation of non-and
A structural similarity search was performed using the program 20 . All crystallographic figures were prepared with PyMOL (DeLano Scientific, http://www.pymol.org).
Modeling and docking studies. Three-dimension models of the N-terminus substrate and phosphorylated 2 were generated by the Chem3D Ultra 10 program (CambridgeSoft, MA, USA), and their geometries were optimized using elbow in PHENIX 43 . The peptide models were generated and optimized using CNS 1.2 45 .
The ADP-and ATP-bound PGM1 models were built by swapping the ADP and ATP molecules with AMP, followed by placing the β-phosphate of the ADP and ATP models on the weak electron density neighboring α-phosphate of the AMP molecule in the PGM1-AMP crystal structure with
Coot. The N-terminus substrate and phosphorylated 2 were then docked into the ATP-and Mutagenesis analyses. All the mutant enzymes were constructed with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), according to the manufacturer's protocol with the primers listed in Supplementary Table 8 . The mutant enzymes were expressed and purified by the same procedure used for the wild-type PGM1 ( Supplementary Fig. 39 ). 
